Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: A crossover study

Stuart M. Sprague, E. A. Ross, S. D. Nath, P. Zhang, R. D. Pratt, R. Krause

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Abstract

Aims: The aim of this cross-over study was to compare the reduction of serum phosphorus (SP) with fixed doses of the non-calcium-containing phosphate binders lanthanum carbonate (LC) and sevelamer hydrochloride (SH) in hemodialysis patients. Methods: Following washout (2 - 3 weeks), 182 patients with SP ≥ 6.0 mg/dl and calcium ≥ 8.4 mg/dl were randomized (1:1) to receive LC (2,250 to 3,000 mg/day) or SH (4,800 to 6,400 mg/day) for 4 weeks. Patients underwent a second washout (2 weeks) and switched to the alternative binder for 4 weeks. Results: At the end of treatment, LC had reduced SP by 1.7 ± 0.1 mg/dl, compared with 1.4 ± 0.1 mg/dl for SH; the difference was not statistically significant in the primary analysis (LOCF, p = 0.133). However, the reduction with LC was significantly greater than with SH in a prespecified key secondary analysis of patients who completed 4 weeks of treatment with each binder (0.5 mg/dl difference, p = 0.007). The reduction of SP was also greater with LC than SH after 1 week of treatment (p = 0.024). Conclusions: Although the primary analysis found no difference between LC and SH in the reduction of SP, a significant difference in favor of LC was observed in patients who completed treatment. The results of this study show interesting trends with respect to onset and duration of action that warrant further investigation in longer-term studies.

Original languageEnglish (US)
Pages (from-to)252-258
Number of pages7
JournalClinical Nephrology
Volume72
Issue number4
DOIs
StatePublished - 2009

Keywords

  • Hyperphosphatemia
  • Lanthanum carbonate
  • Phosphate binder
  • Sevelamer

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: A crossover study'. Together they form a unique fingerprint.

Cite this